Clinical Study
Recombinant Human Leptin Does Not Alter Gut Hormone Levels after Gastric Bypass but May Attenuate Sweet Cravings
Table 1
Baseline characteristics of study participants.
| Parameter | Placebo | Leptin | value* |
| Age (y) | 42.2 ± 2.8 | 51.4 ± 2.0 | 0.02 | Pre-RYGB BMI (kg/m2) | 48.6 ± 1.9 | 47.1 ± 1.8 | 0.58 | BMI at screen (kg/m2) | 35.0 ± 1.1 | 33.3 ± 1.4 | 0.35 | Wt Loss (%) | 30.2 ± 2.3 | 30.7 ± 2.1 | 0.88 | Post-op period (mo) | 44.2 ± 7.4 | 64.6 ± 8.6 | 0.09 | Leptin (ng/mL) | 27.1 ± 3.2 | 21.8 ± 2.5 | 0.20 | Leptin/kg FM (ng/mL/kg) | 0.70 ± 0.06a | 0.66 ± 0.06b | 0.61 |
|
|
Results are expressed as mean ± SEM. subjects per group except as follows: ; . value obtained by two-tailed independent -test.
|